Kalshi and Polymarket Expand Into Health Contracts — Measles, Drug Trials, FDA Approvals Draw Scrutiny
Kalshi and Polymarket have added event contracts tied to US public health outcomes, including measles case-count thresholds settled using CDC data, clinical drug-trial results, and FDA regulatory approvals. Two Democratic senators wrote to the Department of Health and Human Services on November 11 raising concerns about the drug-trial and FDA markets, particularly the risk that people with confidential access to trial data or agency decisions could profit from disclosing it. Kalshi says it has implemented guardrails, such as limiting markets to late-stage trials. The expansion extends the debate over whether some prediction market categories commodify sensitive public outcomes in ways that create genuine harm.
Kalshi and Polymarket have expanded their contract offerings into US public health outcomes. Polymarket's international platform, which operates separately from its US entity, lists a 2026 measles market settled using Centers for Disease Control and Prevention case counts, and Kalshi lists contracts with thresholds for the 2026 US measles total. Both platforms have also added contracts tied to clinical drug-trial results and Food and Drug Administration regulatory approvals. The health-contract expansion follows the broader pattern of the platforms extending into every category of measurable future outcome, but health contracts raise distinct concerns because they touch on matters — disease outbreaks, drug approvals, agency decisions — where the information environment is tightly controlled and where the real-world stakes extend well beyond the traders.
The clinical-trial and FDA-approval contracts have drawn the most pointed scrutiny. Two Democratic senators wrote to the Department of Health and Human Services on November 11, obtained first by CNBC, asking what measures the department has taken to mitigate risks arising from prediction markets on drug trials and regulatory approvals. The core concern is insider information: clinical trials and FDA decisions involve a defined set of people — trial investigators, pharmaceutical company employees, agency reviewers — who possess material non-public information about outcomes that move the contracts. A contract on whether a drug trial will succeed, or whether the FDA will approve a product, creates a direct financial incentive for those insiders to trade on or leak confidential information. Researchers have warned that contracts tied to trials and agency decisions could reward people with confidential access for disclosing it, which would undermine both the integrity of the markets and the confidentiality that clinical research and regulatory review depend on.
Kalshi has defended the health contracts with reference to guardrails and to an informational-access argument. The company says it limits drug-trial markets to late-stage trials, where more information is already public and the universe of material non-public information is narrower, and a Kalshi spokesperson framed the pilot as a way to broaden access to drug-development information — the same forecasting-value argument the platforms make across all their contract categories. The argument is that aggregating dispersed expectations about a drug's prospects produces a useful public signal, in the same way that prediction markets on economic data or elections do. The counterargument is that drug development and public health are domains where the harm from insider trading and information leakage is more concrete than in politics or sports: a leaked trial result can move a pharmaceutical company's stock, affect patients' treatment decisions, and compromise the controlled-disclosure process that regulators rely on, in ways that a leaked election forecast does not.
The measles contracts raise a different and more uncomfortable category of concern. Betting on the number of measles cases in a given year attaches a financial position to the course of a disease outbreak, which critics argue is corrosive regardless of direction — a position that profits from more cases is ghoulish, and a position that profits from fewer cases could, in principle, create perverse incentives around the public-health interventions that reduce case counts. One commentary noted that a measles outbreak resolved by public-health intervention could look like market manipulation to critics, illustrating how poorly the manipulation framework designed for financial contracts maps onto public-health outcomes. The health-contract expansion is the clearest recent example of the broader critique that prediction markets are extending into domains of public life where the commodification of outcomes is ethically fraught, and where the platforms' standard defenses — forecasting value, insider-trading guardrails, voluntary participation — fit awkwardly. As the platforms continue to broaden their contract range in search of volume and growth, the health contracts are likely to sharpen the question of whether there are categories of outcome that should be off-limits to a prediction market, even one that is otherwise legally permitted to operate.
Operators mentioned in this article
Recent updates
CFTC Orders Kalshi to Halt 'Trump Mention' Markets — the Agency Restrains Its Own Protégé
The CFTC notified Kalshi that its 'mention' markets — contracts on what President Trump will say — are under a formal stay, forcing an indefinite pause pending a review of whether the contracts are 'readily susceptible to manipulation.' Kalshi has until December 11 to defend the products, and its CEO reportedly disagrees with the suspension. The action is notable because the CFTC has spent 2026 defending Kalshi against state enforcement; here the same agency is restricting one of Kalshi's own product lines, demonstrating that its role as the platforms' federal protector does not preclude it from policing specific contracts.
Fourth Circuit Rules Against Kalshi in Maryland — Circuit Split Widens to 3-1 With a Notable Dissent
A divided Fourth Circuit panel ruled 2-1 on November 17 that Maryland gaming regulators can pursue enforcement against Kalshi over unlicensed sports betting, rejecting the platform's CFTC-preemption argument. Judge DeAndrea Benjamin dissented, arguing that Kalshi's sports event contracts are 'swaps' under exclusive CFTC oversight — the first appellate dissent on the pro-Kalshi side of the question. The ruling makes the Fourth Circuit the third appeals court to rule against Kalshi, deepening the split to three circuits against (Fourth, Sixth, Ninth) and one for (Third), with the Supreme Court cert petition pending.
CFTC and DOJ Sue Louisiana and Arkansas as Federal-State Fight Turns Openly Hostile
Louisiana Attorney General Liz Murrill won a temporary restraining order on November 12 against 31 prediction market entities, including Kalshi, Polymarket, Robinhood, and Coinbase, with a preliminary injunction hearing set for November 30. The CFTC — now joined by the Department of Justice — sued both Louisiana and Arkansas to block the state enforcement, marking Louisiana as the twelfth state the agency has taken to court. The dispute has turned personal: Murrill called CFTC Chairman Michael Selig an 'obsequious standard bearer' for the platforms, while Selig characterized her lawsuit as 'naked lawfare.' The DOJ's involvement escalates the federal response beyond the CFTC acting alone.